☰ Category

Neuropharmacological & Biochemical Evaluation for Schizophrenia


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days


Check Your Delivery Options

Rs. 4,396

Availability: In stock

  • Product Description

Schizophrenia a chronic, debilitating psychiatric disorder comprises of positive and negative symptoms along with cognitive and attention impairments. Antipsychotic drugs available in the market for treatment of schizophrenia have either been unable to treat all the symptoms of schizophrenia or accompany a lot of side-effects. Ketamine, a NMDA receptor antagonist was used to model psychotic symptoms in mice. Herbal compounds (CDRB01 and CDRP01) normalized the ketamine induced increased NR1A protein expression, reduced acetylcholinesterase activity as well as monoamine oxidase activity but did not show any extrapyramidal side effects. Estimation of brain neurotransmitter level revealed that both compounds reduced DA and 5-HT content in the cortex, striatal and hippocampal regions. CDR-B01 was effective in ameliorating positive, negative as well as cognitive dysfunctions induced by ketamine. Whereas compound CDRP01 significantly attenuated ketamine induced increased D1 receptor expression but had no significant effects on D2 expression, showed efficacy in the negative and cognitive symptoms only. They normalized GSH level, reduced lipid peroxidation & nitrite but increased SOD level.

Product Specifications
SKU :COC84970
AuthorVrish Dhwaj Ashwlayan,Reena Kumari and Gautam Palit
Number of Pages156
Publishing Year2013-02-13T00:00:00.000
Edition1 st
Book TypePharmacology
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-10-08 00:00:00
0 Review(s)